PPTA Twitter

PlasmaProteins
PlasmaProteins . @DonCoppo — donors definitely deserve our gratitude for the dedication they show in supporting people living with rare, serious, & chronic diseases. With our friends at @HIYDglobal , we all agree #PlasmaDonorsSaveLives ! twitter.com/DonCoppo/status/1121060045888868358
1 day ago.
PlasmaProteins
PlasmaProteins It’s important to understand that #plasma used to manufacture #plasmaprotein therapies is intrinsically different from blood components used for transfusion. Differences include the way that plasma is collected & the complexities of the production process. bit.ly/2Qo4bsI
1 day ago.

BPAC Meets to Hear Research Program Updates

On June 20, from 9:30 a.m. to noon (ET), the Blood Products Advisory Committee (BPAC) met by teleconference to hear updates of research programs in the Laboratory of Plasma Derivatives in the Division of Hematology Research and Review, which is under the Office of Blood Research and Review (OBRR) at the Center for Biologics Evaluation and Research (CBER),

U.S. Food and Drug Administration. Before the updates, Industry Representative Toby Simon (CSL Behring), whose term ends Sept. 30, was thanked among others for his service. [Update: Dr. Simon's service on the Committee will continue through the Nov. 17-18 meeting.] Of note, Carolyn Wilson, Associate Director for Research at CBER, announced the initiation of a CBER Peer Mentoring Group and the establishment of two new governance bodies to oversee research priorities and budget and resource planning, namely the Resource Committee and the Regulatory Science Council; the two new bodies report to the Center Director and Deputy Director. (Dr. Wilson also discussed the Resource Committee and the Regulatory Science Council in a June 21 blog on CBER's laboratories in the Life Sciences-Biodefense Complex.) From OBRR, Basil Golding presented on coagulation immunology, protein structure and function, blood-borne viruses, oxygen-carrying compounds, and platelet structure and function, and Dorothy Scott presented a comparative study of factor IX immunogenicity in a mouse model of hemophilia B, a study to improve antibody-mediated neutralization by HCV-specific immune globulins, a project aimed at increasing U.S. preparedness for potential expansion of smallpox vaccination, a study involving Zika virus inactivation in whole blood via ultraviolet irradiation and photosensitizers, and a project about hemolytic activity in licensed immune globulin intravenous products. At noon, BPAC entered into a closed session discussion about site visit reports for OBRR research programs.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100